Advanced Search
Amicus Therapeutics

Amicus Therapeutics

A biotechnology company developing therapies to cure rare diseases

All edits by  Andrey Pyankov 

Edits on 30 Apr, 2019
Andrey Pyankov
Andrey Pyankov approved a suggestion from Golden's AI on 30 Apr, 2019
Edits made to:
Article (+25/-25 characters)

On September 8, 2005 Amicus Therapeutics completed their series C funding round with $55 million in funding from Quaker BioVentures (lead investor), Radius Ventures, Prospect Venture PartnersProspect Venture Partners, Palo Alto Investors, New Enterprise Associates, Garden State Life Sciences Venture, Frazier Healthcare Partners, Canaan Partners, and CHL Medical Partners.

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.